Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery (PREOPRAD)

17 novembre 2026 mis à jour par: Paola Anna Jablonska, Fundacion Miguel Servet

Randomized Phase II/III Study Comparing Preoperative Radiosurgery Versus Postoperative Radiosurgery in Patients With Brain Metastases Eligible for Surgery: Correlation With Histopathological Factors and Radiomic Analysis.

The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.

More specifically, the study seeks to:

  • Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
  • Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
  • Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.

PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.

The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.

Aperçu de l'étude

Description détaillée

Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Badajoz
      • Badajoz, Badajoz, Espagne, 06080
        • Pas encore de recrutement
        • Hospital Universitario de Badajoz
        • Contact:
    • Galicia
      • Vigo, Galicia, Espagne, 36214
        • Pas encore de recrutement
        • Hospital do Meixoeiro
        • Contact:
    • Madrid
      • Madrid, Madrid, Espagne, 28034
        • Recrutement
        • Hospital Universitario Ramón y Cajal
        • Contact:
      • Madrid, Madrid, Espagne, 28034
    • Navarre

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age ≥18 years.
  • Histologically confirmed solid tumor with one to four brain metastases.
  • At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
  • Karnofsky Performance Status (KPS) ≥70.
  • Life expectancy ≥3 months.
  • Ability to undergo MRI examinations.
  • Written informed consent provided.

Exclusion Criteria:

  • Brain metastases from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
  • Prior radiotherapy to the index lesion.
  • Leptomeningeal disease at baseline.
  • Contraindication to surgery or stereotactic radiosurgery.
  • Pregnancy or breastfeeding.
  • Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: preoperative radiosurgery

preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

Autres noms:
  • radiochirurgie

Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm

Autre: postoperative radiosurgery

standard treatment, consisting of surgical resection followed by irradiation of the tumor bed

radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

Autres noms:
  • radiochirurgie

Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Locoregional adverse event-free survival
Délai: From randomization to the first locoregional adverse event, assessed up to 12 months after randomization

A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed.

From randomization to the first locoregional adverse event, assessed up to 12 months after randomization

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Meningeal Failure Rate
Délai: 6 and 12 months after randomization.

Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI).

6 and 12 months after randomization.
Symptomatic Radiation Necrosis Rate
Délai: 6 and 12 months after randomization.

Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation.

6 and 12 months after randomization.
Local Control Rate
Délai: 6 and 12 months after randomization.

Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI.

6 and 12 months after randomization.
Distant Brain Failure-Free Survival
Délai: 6 and 12 months after randomization.

Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s).

6 and 12 months after randomization.
Overall Survival
Délai: 6 and 12 months after randomization.

Time from randomization to death from any cause.

6 and 12 months after randomization.

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Time to Whole-Brain Radiotherapy (WBRT)
Délai: From randomization until administration of WBRT, up to 42 months.

Time from randomization to the administration of whole-brain radiotherapy (WBRT).

From randomization until administration of WBRT, up to 42 months.
Health-Related Quality of Life
Délai: Baseline, and at 3, 6, 12, 18, and 24 months after treatment.

Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden).

Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
Length of Hospital Stay
Délai: From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.

Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge.

From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
Treatment Delay
Délai: From treatment planning to treatment completion, up to 42 months.

Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment.

From treatment planning to treatment completion, up to 42 months.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 septembre 2026

Achèvement primaire (Estimé)

30 mars 2030

Achèvement de l'étude (Estimé)

31 mars 2030

Dates d'inscription aux études

Première soumission

3 novembre 2026

Première soumission répondant aux critères de contrôle qualité

17 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner